These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 23994384

  • 1. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
    Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC.
    J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
    [Abstract] [Full Text] [Related]

  • 2. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
    Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW, Al-Judaibi B, Renner EL, Lilly LB.
    Ann Hepatol; 2014 Jan; 13(5):525-32. PubMed ID: 25152985
    [Abstract] [Full Text] [Related]

  • 3. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC.
    AIDS; 2015 Jan 02; 29(1):53-8. PubMed ID: 25387314
    [Abstract] [Full Text] [Related]

  • 4. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group.
    J Hepatol; 2013 Sep 02; 59(3):434-41. PubMed ID: 23669289
    [Abstract] [Full Text] [Related]

  • 5. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    J Hepatol; 2013 Aug 02; 59(2):205-12. PubMed ID: 23542346
    [Abstract] [Full Text] [Related]

  • 6. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.
    Clin Gastroenterol Hepatol; 2013 Aug 02; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [Abstract] [Full Text] [Related]

  • 7. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
    Miailhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, Sogni P, Fontaine H, Rosenthal E, Winnock M, Loko MA, Wittkop L, Dabis F, Salmon D, ESCMID European Study Group on Viral Hepatitis.
    Liver Int; 2015 Sep 02; 35(9):2090-9. PubMed ID: 25650873
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A, WEF Study Group.
    J Hepatol; 2013 Oct 02; 59(4):658-66. PubMed ID: 23707373
    [Abstract] [Full Text] [Related]

  • 9. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
    Coilly A, Dumortier J, Botta-Fridlund D, Latournerie M, Leroy V, Pageaux GP, Agostini H, Giostra E, Moreno C, Roche B, Antonini TM, Guillaud O, Lebray P, Radenne S, Saouli AC, Calmus Y, Alric L, Debette-Gratien M, De Ledinghen V, Durand F, Duvoux C, Samuel D, Duclos-Vallée JC.
    PLoS One; 2015 Oct 02; 10(9):e0138091. PubMed ID: 26394142
    [Abstract] [Full Text] [Related]

  • 10. High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy.
    Verna EC, Shetty K, Lukose T, Terry N, Mentore K, Olsen SK, Fox AN, Dove LM, Brown RS.
    Liver Int; 2015 Feb 02; 35(2):510-7. PubMed ID: 24905624
    [Abstract] [Full Text] [Related]

  • 11. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
    Bailly F, Virlogeux V, Dufour C, Pradat P, Hézode C, Larrey D, Alric L, Samuel D, Bourlière M, Métivier S, Zarski JP, Fontaine H, Loustaud-Ratti V, Serfaty L, Bronowicki JP, Carrat F, Zoulim F, CUPIC Study Group.
    Clin Res Hepatol Gastroenterol; 2015 Sep 02; 39(4):443-50. PubMed ID: 25636238
    [Abstract] [Full Text] [Related]

  • 12. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S, Solas C, Motte A, Moreau J, Borentain P, Mokhtari S, Botta-Fridlund D, Dhiver C, Portal I, Ruiz JM, Ravaux I, Bregigeon S, Poizot-Martin I, Stein A, Gérolami R, Brouqui P, Tamalet C, Colson P.
    J Med Virol; 2014 Nov 02; 86(11):1868-76. PubMed ID: 25052594
    [Abstract] [Full Text] [Related]

  • 13. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS, Hwang EW, Thomas IC, Mole LA, Cheung RC, Backus LI.
    Clin Gastroenterol Hepatol; 2013 Aug 02; 11(8):1021-7. PubMed ID: 23524130
    [Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.
    Clin Gastroenterol Hepatol; 2013 Nov 02; 11(11):1503-10. PubMed ID: 23707354
    [Abstract] [Full Text] [Related]

  • 15. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
    Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP.
    Liver Transpl; 2013 Jul 02; 19(7):690-700. PubMed ID: 23696372
    [Abstract] [Full Text] [Related]

  • 16. [HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].
    Herzer K, Papadopoulos-Köhn A, Timm J, Paul A, Jochum C, Gerken G.
    Dtsch Med Wochenschr; 2013 Sep 02; 138(36):1759-64. PubMed ID: 24002874
    [Abstract] [Full Text] [Related]

  • 17. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.
    Virlogeux V, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F.
    J Viral Hepat; 2014 Sep 02; 21(9):e98-e107. PubMed ID: 24612466
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
    Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra MÁ, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R, Alhambra Spanish Study Group.
    World J Gastroenterol; 2015 Aug 14; 21(30):9163-74. PubMed ID: 26290644
    [Abstract] [Full Text] [Related]

  • 19. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ, Lancaster JW.
    Clin Ther; 2012 Sep 14; 34(9):1857-82. PubMed ID: 22951253
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.